Progress Through Partnership
We are building a preeminent oncology company by leveraging the intelligence, experience and entrepreneurial spirit of our internal teams with that of medical, academic and biopharmaceutical collaborators. Our significant scientific, medical and regulatory expertise combined with our openness to creative collaboration, make Progenics an ideal partner for organizations that share our enthusiasm for innovation and improved therapeutic and diagnostic options for cancer patients.
Progenics evaluates opportunities to expand our focused oncology pipeline on an on-going basis, including in- and out-licensing arrangements and product and company acquisitions. Upon approval of product candidates we expect to commercialize some directly and explore marketing partnerships for others.
Get more information on how to become a partner.
HIV Viral Entry Inhibitor
PRO 140 is a humanized anti-CCR5 monoclonal antibody created at Progenics and now developed by CytoDyn Inc. PRO 140 is in Phase 2 testing as a treatment for human immunodeficiency virus (HIV) infection. MORE>
Antibodies Targeting C.diff Toxins
C. difficile is a pair of humanized antibodies that neutralize the disease-causing toxins of Clostridium difficile. PRO 391 provides a non-antibiotic approach to managing this important and life-threatening disease. MORE>